Abstract
Objectives: Ovarian tumors have been shown to contain a rare population of quiescent cancer stem cells (CSCs) that survive cytotoxic chemotherapy and drive tumor resurgence. Direct targeting of the ovarian CSC via CSC-specific cell surface markers is a viable strategy to block disease recurrence and metastasis. The sialyl Tn (STn) antigen is a carbohydrate moiety that is present on protein markers of CSCs in pancreatic, colon and gastric malignancies. Our objective was to characterize the expression of STn in human ovarian cancer cell lines and primary serous carcinomas. Furthermore, we sought to investigate the potential co-expression of STn with the known ovarian CSC marker CD133, evaluate the relative ability of STn + and STn- cells to grow in an anchorage independent manner and assess the effect of α -STn antibody-drug conjugates on ovarian cancer cell viability in vitro.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
